Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

11.01 +0.02 (+0.14%)
Streaming Delayed Price Updated: 12:45 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
18 19 Next >
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
Cathie Wood is bullish about these stocks. And so are Wall Street analysts. 
Via The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
 
Via Benzinga
Expert Ratings for Intellia Therapeutics
 
Via Benzinga
The Latest Analyst Ratings for Intellia Therapeutics
 
Via Benzinga
Analyst Ratings for Intellia Therapeutics
 
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time. 
Via InvestorPlace
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The growth-focused money manager is making moves. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Friday
  Friday saw 23 companies set new 52-week lows. 
Via Benzinga
Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates
 
Via Benzinga
Recap: Intellia Therapeutics Q3 Earnings
Intellia Therapeutics (NASDAQ:NTLA) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
 
Via Benzinga
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years
Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow. 
Via The Motley Fool
7 Analysts Have This to Say About Intellia Therapeutics
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
 
Via Benzinga
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
Both stocks have fallen brutally this year, but only one has a chance to recover soon. 
Via The Motley Fool
3 Mid-Caps That Could Double in 2023
Mid-cap land has long been regarded as the ‘sweet spot’ for equity investors. Here are three mid-caps Wall Street sees as two-baggers over the next 12 months. 
Via MarketBeat
7 ‘Next Big Things’ for Investors to Buy for 2023
The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown. 
Via InvestorPlace
Ulta Beauty To Rally Around 22%? Here Are 10 Other Price Target Changes For Friday
 
Via Benzinga
NTLA Stock Falls as Intellia Therapeutics Announces Public Offering
Intellia Therapeutics (NTLA) stock is falling hard on Thursday after the company announced a public stock offering of 6.6 million shares. 
Via InvestorPlace
Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing
Here's how Ark Invest's top holdings have performed in 2022. 
Via Investor's Business Daily
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
  Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday. 
Via Benzinga
Earnings Preview For Intellia Therapeutics
Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
3 Cathie Wood Stocks to Buy and Hold for 10 Years
The risks are formidable, but the chances of a massive gain are too much to pass up. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.